Pharmacogenetics and pharmacogenomics in rheumatology

Zoltán Szekanecz, Bertalan Meskó, Szilard Poliska, Andrea Váncsa, Szilvia Szamosi, Edit Végh, Enikö Simkovics, Judit Laki, Júlia Kurkó, Timea Besenyei, Katalin Mikecz, Tibor T. Glant, László Nagy

Research output: Contribution to journalArticlepeer-review

22 Scopus citations


Pharmacogenetics and pharmacogenomics deal with possible associations of a single genetic polymorphism or those of multiple gene profiles with responses to drugs. In rheumatology, genes and gene signatures may be associated with altered efficacy and/or safety of anti-inflammatory drugs, disease-modifying antirheumatic drugs (DMARDs) and biologics. In brief, genes of cytochrome P450, other enzymes involved in drug metabolism, transporters and some cytokines have been associated with responses to and toxicity of non-steroidal anti-inflammatory drugs, corticosteroids and DMARDs. The efficacy of biologics may be related to alterations in cytokine, chemokine and FcγR genes. Numerous studies reported multiple genetic signatures in association with responses to biologics; however, data are inconclusive. More, focused studies carried out in larger patient cohorts, using pre-selected genes, may be needed in order to determine the future of pharmacogenetics and pharmacogenomics as tools for personalized medicine in rheumatology.

Original languageEnglish (US)
Pages (from-to)325-333
Number of pages9
JournalImmunologic Research
Issue number2-3
StatePublished - Jul 2013
Externally publishedYes


  • Biologics
  • DMARDs
  • Genetic signature
  • NSAIDs
  • Pharmacogenetics
  • Pharmacogenomics
  • Rheumatoid arthritis
  • SNP

ASJC Scopus subject areas

  • Immunology


Dive into the research topics of 'Pharmacogenetics and pharmacogenomics in rheumatology'. Together they form a unique fingerprint.

Cite this